Postdoctoral Research Scientist
I completed a BSc in Biochemistry at Queen's University in Canada followed by a MSc in Forensic Science at King's College London. Following 2 years as a research technician with the CRY Cardiovascular Pathology laboratory, I completed a BHF-sponsored PhD in Cardiovascular Sciences at St. George's, University of London.
My PhD research was focussed on the cardiac impact of kinase inhibitors used as cancer treatments, particularly in the setting of stress such as hypertension. Primarily, I was interested in the concept of the RAF paradox and the development of novel 'paradox breaking' inhibitors.
Since completion of my PhD in September 2022, I have started as a Postdoctoral Research Scientist in Professor Paul Riley's group. As part of a MRC programme, I am studying immunomodulation following cardiac injury, with a particular focus on cardiac lymphangiogenesis, to ascertain the optimal local injury environment for tissue repair after a heart attack.
Erratum to ‘Defining Commotio Cordis’: The American Journal of Cardiology Volume 124, Issue 10, 15 November 2019, Pages 1649-1650 (The American Journal of Cardiology (2019) 124(10) (1649–1650), (S0002914919309415), (10.1016/j.amjcard.2019.08.006))
Maron BJ. et al, (2023), American Journal of Cardiology, 193
Abstract P3113: RAF 'Paradox Breaker' Inhibitor, PLX8394, Enhances Inflammation And Apoptosis In Murine Hypertension In Vivo
Cooper S. et al, (2023)
Cardiomyocyte BRAF is a key signalling intermediate in cardiac hypertrophy in mice.
Alharbi HO. et al, (2022), Clin Sci (Lond), 136, 1661 - 1681
PKN2 deficiency leads both to prenatal 'congenital' cardiomyopathy and defective angiotensin II stress responses.
Marshall JJT. et al, (2022), Biochem J, 479, 1467 - 1486
Of Mouse and Man: Cross-Species Characterization of Hypertensive Cardiac Remodeling.
Cooper STE. et al, (2022), Int J Mol Sci, 23